Search

everythinglearnresearchcommunity

for

Search:↓

Some patients on immunosuppressants had a weaker immune response to the Sinovac-CoronaVac COVID-19 vaccine.

Certain cancer drugs interact with skin bacteria to cause acne-like rashes.

A 3-month treatment improved PCOS symptoms and reduced certain immune proteins.

Treatment improved PCOS symptoms and reduced BMI and certain immune factors.

Smaller nanoemulsions can penetrate skin and hair follicles better, which may be useful for delivering drugs and vaccines through the skin.

UV radiation causes skin cancer, but sunscreens and certain drugs can help prevent it.

COVID-19 may affect male fertility and women might have better outcomes due to hormonal and immune differences.

COVID-19 patients often experience hair loss and scalp pain, which may be related to the severity of their infection and treatment drugs.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Systemic lupus erythematosus is a chronic disease causing inflammation and various symptoms, mainly in young women, treated with anti-inflammatory and immunosuppressive drugs.

New treatments and strategies are needed for Alopecia Areata, focusing on immune response and better trial designs.

Paternal drug exposure can harm fertility, pregnancy outcomes, and offspring health, with specific drugs linked to various reproductive issues.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

Propylthiouracil, a thyroid medication, can cause skin blood clots and immune-related blood vessel inflammation.

Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.

Methotrexate can temporarily suppress certain immune responses without killing immune cells, potentially helping treat autoimmune diseases.

New treatments for alopecia areata may target specific immune cells and pathways involved in hair loss.

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

The document concludes that primary scarring alopecias cause permanent hair loss, have unpredictable outcomes, and lack definitive treatments, requiring personalized care.

A new skin disease in four Labrador retrievers responded well to immunosuppressive treatment.

Skin fungal infections are more common in older adults due to factors like obesity, poor circulation, reduced mobility, and weakened immune defenses from certain medications.

COVID-19 may cause common hair loss due to stress, immune response, medications, and other health issues.

Statins may help treat alopecia areata by reducing harmful immune interactions.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

Toxic Epidermal Necrolysis is a rare, serious skin condition that can affect anyone, is more common in women, and may be linked to genetics, with a 20% mortality rate mainly due to sepsis.

New targeted therapies for hair loss from alopecia areata show promise, with personalized treatment expected in the future.

Microneedles are a promising method for drug delivery, offering efficient and convenient alternatives with fewer side effects.

Leflunomide is more likely to help treat alopecia areata than cause it.

Omics techniques are needed to understand the scalp microbiome's role in alopecia areata for new treatments.